Abstract
Furoxan derivatives with in vitro cytotoxic activity were investigated as antitumoral agents in vivo. The compounds were tested in murine models of both CCRFS-180 II sarcoma and mammary adenocarcinoma. Two of the furoxan derivatives considered here, 3-formyl-4-phenyl-1,2,5-oxadiazole N2-oxide and 3-carbonitrile-4-phenyl-1,2,5-oxadiazole N2-oxide, present in vivo antitumoral activity. They were able to produce more than 90% of tumoral necrosis under the experimental protocol of administration and posology employed. NO-releasing capacity of furoxans may explain the anti-neoplastic activity of these compounds.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Antineoplastic Agents / chemical synthesis*
-
Antineoplastic Agents / pharmacology*
-
Antineoplastic Agents / toxicity
-
Cell Line, Tumor
-
Chemical Phenomena
-
Chemistry, Pharmaceutical
-
Chemistry, Physical
-
Female
-
Mammary Neoplasms, Experimental / drug therapy
-
Mammary Neoplasms, Experimental / pathology
-
Mice
-
Mice, Inbred BALB C
-
Neoplasm Transplantation
-
Oxadiazoles / chemical synthesis*
-
Oxadiazoles / pharmacology*
-
Oxadiazoles / toxicity
-
Quinoxalines / pharmacology
-
Sarcoma, Experimental / drug therapy
-
Sarcoma, Experimental / pathology
Substances
-
Antineoplastic Agents
-
Oxadiazoles
-
Quinoxalines
-
furoxans
-
quindoxin